Bloomberg Markets & Finance via Youtube


Nov.02 — Tiziana Life Sciences PLC is launching a clinical trial in Brazil involving humans where they will be treated with a nasally administered Foralumab, a monoclonal antibody. Gabriele Cerrone, the chief executive officer, speaks on “Bloomberg Markets.”

READ ALSO  SE: Nobel Laureate Spence: Controlling Virus May Cause Economic Dip